TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 20.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 20.8nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 23nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 32.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 34.1nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 35.7nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 36.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 37.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 47.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 50.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 52.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 60nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 60.3nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 62.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 62.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 63.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 65.5nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 70.3nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 72nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 72.1nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 81.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 98.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 99.7nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 120nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 124nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 124nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 130nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 141nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 145nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 147nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 150nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 159nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 159nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 181nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 184nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 185nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 194nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 206nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 207nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 224nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 232nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 244nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 255nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 256nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 269nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 295nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 373nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair